Navigation Links
Schering-Plough Announces Filing of U.S. Application for OTC ZEGERID(R)
Date:3/11/2008

s the gastric pH and thus protects omeprazole from acid degradation.

Important Safety Information about ZEGERID

The most frequently reported adverse events with ZEGERID are headache, diarrhea, and abdominal pain. Symptomatic response to therapy does not preclude the presence of gastric malignancy. Atrophic gastritis has been noted occasionally in gastric corpus biopsies from patients treated long term with omeprazole.

ZEGERID contains sodium bicarbonate. This should be taken into consideration for patients on a sodium-restricted diet.

ZEGERID is contraindicated in patients with known hypersensitivity to any component of the formulation.

About Schering-Plough

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. In November 2007, Schering-Plough acquired Organon BioSciences, with its Organon human health and Intervet animal health businesses, marking a pivotal step in the company's ongoing transformation. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is http://www.schering-plough.com.

SCHERING-PLOUGH DISCLOSURE NOTICE: The information in this press release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the future regulatory approval and potential for ZEGERID. Forward-looking statements relate to expectations or forecasts of future events. Schering-Plough does
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year
2. Schering-Plough and OraSure Technologies Sign International Collaboration for Rapid Point-of-Care Oral Hepatitis C Test
3. Schering-Plough Announces Organizational Changes at Schering-Plough Research Institute
4. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
5. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
6. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
7. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
8. Schering-Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter, Full-Year Financial Result
9. Schering-Plough Wins Three of Scrips Top Pharma Industry Awards
10. Schering-Plough Completes Acquisition of Organon BioSciences
11. Schering-Plough Receives Approval from European Commission for Planned Acquisition of Organon BioSciences N.V.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... Genedata, a leading provider of ... science research, today announced the release of ... its enterprise solution for biologics R&D. This first-in-class ... discovery and development of novel biotherapeutics. Version 5.0 ... protein optimization and developability requirements. Genedata will present ...
(Date:5/4/2015)... 2015 China Cord Blood Corporation (NYSE: ... leading provider of cord blood collection, laboratory ... services, today announced that the Company has been informed ... Hong Kong listed company and a ... agreement (the "Agreement") to purchase the Company,s outstanding 7% ...
(Date:5/4/2015)... 2015   Intrexon Corporation (NYSE: XON ... financial results after the market closes on May 11, ... day at 5:30 PM ET to discuss the results ... conference call may be accessed by dialing 1-888-346-3959 (Domestic ... "Intrexon Conference Call."  Participants may also access the live ...
(Date:5/1/2015)...  Northwest Biotherapeutics (NASDAQ: NWBO ) ("NW Bio"), ... for solid tumor cancers, announced today that the Company ... a $40 million investment from Woodford investment funds in ... million in NW Bio on November 19, 2014.  On ... the Company for a further $40 million investment in ...
Breaking Biology Technology:Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 2Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 3Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 4China Cord Blood Corporation Receives Notice of a Transaction Regarding its 7% Senior Convertible Notes Due 2017 Held by KKR 2China Cord Blood Corporation Receives Notice of a Transaction Regarding its 7% Senior Convertible Notes Due 2017 Held by KKR 3Intrexon to Announce First Quarter 2015 Financial Results on Monday, May 11, 2015 2NW Bio Closes On $28.5 Million Second Tranche Of Woodford $40 Million Financing 2NW Bio Closes On $28.5 Million Second Tranche Of Woodford $40 Million Financing 3
... Neogen Corporation (Nasdaq: NEOG ) announced today that ... which ended Nov. 30, increased 33% from the previous year,s ... or $0.26 per share, compared to the prior year,s $0.20. ... to the prior year,s $35,251,000. Year-to-date revenues for the first ...
... 2011 Vaccinex, Inc. announced today that it has ... 1 clinical trial to assess the safety, tolerability, pharmacokinetics ... patients with advanced solid tumors. (Logo: ... antibody that blocks the activity of semaphorin 4D (SEMA4D). ...
... 4, 2011 Reportlinker.com announces ... report is available in its ... title=,The 2011 Clinical Chemistry And ... Product Development Opportunities And Business ...
Cached Biology Technology:Neogen Reports 33% Increase in Net Income 2Neogen Reports 33% Increase in Net Income 3Neogen Reports 33% Increase in Net Income 4Neogen Reports 33% Increase in Net Income 5Vaccinex, Inc. Initiates Clinical Trial of Novel Therapeutic Antibody in Cancer Patients With Advanced Solid Tumors 2Reportlinker Adds The 2011 Clinical Chemistry And Immunodiagnostics Markets US, Europe, Japan: Product Development Opportunities And Business Expansion Strategies For Instrument And Reagent Suppliers 2
(Date:3/30/2015)... 26, 2015 Research and Markets ( ... "Global Gesture Recognition Market in Automotive Sector 2014-2018" ... the Global Gesture Recognition market in Automotive Sector to ... 2013-2018. Gesture recognition is the ability of ... of an individual. Gesture recognition technology can be 2D-based ...
(Date:3/24/2015)... , March 24, 2015   Crossmatch ™, ... today announced that its U.are.U ® 4500 ... Goorin Bros . to achieve PCI compliance ... secures access to the POS terminal, protecting the ... of data breaches. With one-third ...
(Date:3/20/2015)... Research and Markets ( http://www.researchandmarkets.com/research/4stcg3/india_sensors ... "India Sensors Market Forecast and Opportunities 2020" ... market is projected to grow at a CAGR ... automotive, industrial and healthcare sectors are the key ... addition, adoption of MEMS technology in sensors is ...
Breaking Biology News(10 mins):Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3
... that features of their landscape have a profound effect on ... the open access journal BMC Genetics found that ... forest foliage, can separate giant pandas into isolated genetic groups. ... with a team of researchers to study giant pandas in ...
... of the Finnish Forest Research Institute, Metla, "feel relaxed and ... of us know that there is also scientific evidence about ... other natural, green settings can reduce stress, improve moods, ... may also strengthen our immune system by increasing the activity ...
... was revolutionized in 1922 when insulin was isolated from dogs. ... more manageable for patients. Now, human medicine has returned the ... A University of Missouri researcher is using a continuous glucose ... to help treat dogs and other animals. The device, which ...
Cached Biology News:Diabetes monitoring device benefits man and man's best friend 2
... the smallest electronic pressure controller available measuring ... configured this unit specifically for the analytical ... in carrier gas flow control, microfluidic flow ... hydro-dynamic focusing, the OEM-EPC offers external pressure ...
... Slide Table is designed for moving loads ... provides maximum force output while limiting overall ... of stainless steel ball bearings guided on ... self-compensating shock absorbers provide energy absorption and ...
... is obtained from non-demolished blood ... fasted donors. The donors are ... and are maintained on an ... Protein Concentration : 85 mg/ml ...
Alkaline Phosphatase (E. coli C75), 100 units. Removes 5'-phosphates from DNA. Category: Nucleotides & Enzymes & Biochemicals, Modifying Enzymes, Alkaline Phosphatases....
Biology Products: